Webinar
2024 Leadership Insights Series
We’re committed to sharing valuable insights with hospital and health system leaders like you.
Making connections, spotting trends, advancing strategies
We heard that frequent, meaningful communication is important to you. That’s why we created this series. Through this channel, we’re focused on creating connections and facilitating discussions around industry trends, market dynamics, and our long-term organizational strategy.
Lisa Scholz, VP of 340B Enterprise Strategy
340B Year-in-Review
Join Lisa Scholz, VP, 340B Enterprise Strategy at Cencora for a recap of all things 340B in 2024. Lisa will share about 340B policies and where they stand today as well as how Accelerate Pharmacy Solutions' 340B team can partner with you. She will also talk about innovation in the 340B space and where she sees the landscape going in 2025.
Beth Mitchell, VP of US Public Policy and Advocacy
Public Policy and Advocacy State of the Union
Join Beth Mitchell, VP, US Public Policy and Advocacy for a state of the union on Public Policy and Advocacy. Beth will cover key updates that took place in 2023, along with what has occurred so far in 2024. She will also touch on how Cencora is partnering to make change in this space.
Lung-I Cheng, PhD, VP Cell and Gene Therapy Service Line and Louis Cicchini, PhD, Director Scientific Affairs
The Transformative Value of Cell and Gene Therapy
In this engaging discussion of these important therapies addressing critical unmet patient needs with curative intent, Dr. Cicchini touches on autologous cell therapy, where a patient’s own cells are used as the therapy; allogeneic cell therapy, using a donor’s cells; and gene therapy, where the DNA inside cells is changed to provide therapeutic benefit. With cell and gene therapy expanding in therapeutic areas like dermatology, immunology, ophthalmology, endocrinology, neurology, musculoskeletal, hematology and oncology, the FDA is predicting 10-20 new cell and gene therapy drug approvals annually by 2025. To support the complex and challenging patient journey, Dr. Cheng explains how his team focuses on enabling access to cell and gene therapies, collaborating with developers to enhance distribution, streamline logistics, and provide comprehensive patient support. He shares an example of a patient suffering from ALD making his way through the process, then discusses the significantly higher production costs of cell and gene therapies and how that compares to their value.
